Kidney Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024 - Takeaways - MDSpire
Advertisement
Kidney Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2024.
The TEO2 study found no benefit in adding nivolumab to Tavo nib after prior immunotherapy in metastatic RCC patients.
2
The Sunni forecast trial established eppel as a reasonable treatment for nonclear cell RCC, showing superior 12-month overall survival compared to standard care.
3
A phase three study demonstrated that the combination of alatinib and anti-PDL1 showed improved progression-free survival over sunitinib in metastatic clear cell RCC.
4
The TEO2 trial suggests that IOTK I combinations should not be used in patients who have recently progressed on immunotherapy.
5
Preliminary data from the tacito trial highlights the importance of the gut microbiome in influencing immunotherapy responses in RCC.
